- Home »
- Quarterly Results »
- Concord Drugs Q1 Results Total Revenue of ₹1,169.29 Lakhs and Profit After Tax of ₹2.73 Lakhs
Concord Drugs Q1 Results Total Revenue of ₹1,169.29 Lakhs and Profit After Tax of ₹2.73 Lakhs
Concord Drugs Q1 Results for 2024-2025 showed a 74% QoQ drop in total income to ₹1,169.29 lakhs, and a 94.2% QoQ decrease in operating profit to ₹2.73 lakhs, Concord Drugs Q1 Results also highlighted a 94.2% QoQ reduction in profit after tax.
by P Nandhini
Updated Sep 13, 2024
Table of Content
Concord Drugs Q1 Results 2024 - 2025: Concord Drugs reported their Q1 results for the year 2024-2025 on 10 September 2024, showing a mixed performance compared to the previous quarter. The company’s net sales from operations decreased by 19.84% QoQ, from ₹4,492.45 lakhs in the previous quarter to ₹1,169.29 lakhs in Q1 2024-2025.
This drop in revenue highlights a significant decline of 74% quarter-over-quarter (QoQ), reflecting challenges faced in their manufacturing and sales operations during this period. In terms of profitability, Concord Drugs experienced a decrease in profit with the earnings per share falling to ₹0.03 in Q1 2024-2025, compared to ₹0.47 in the previous quarter.
The company’s total comprehensive income for the period also saw a sharp decline of 94.2% QoQ. Despite these setbacks, the company has been actively addressing the discrepancies in its financial results, as noted in its communication with BSE Limited.
Moving forward, you can expect Concord Drugs to focus on improving its operational efficiency and financial performance to recover from this quarter’s results.
For More Q1 results check our Twitter Page
Concord Drugs Q1 Results 2024 - 2025
Here is a summary of Concord Drugs's Q1 results for 2024-2025:
The table below highlights the key financial metrics for Concord Drugs for the period ending 30th June 2024. The figures reflect a significant decline compared to the previous quarter.
| Metric | Q1 2024-2025 | Previous Quarter | QoQ Change |
|---|---|---|---|
| Net Sales from Operations | ₹1,169.29 lakhs | ₹4,492.45 lakhs | -74% |
| Other Income | ₹0.00 lakhs | ₹0.93 lakhs | -100% |
| Total Revenue | ₹1,169.29 lakhs | ₹4,493.38 lakhs | -74% |
| Cost of Material Consumed | ₹866.98 lakhs | ₹3,365.90 lakhs | -74.3% |
| Total Expenses | ₹1,165.20 lakhs | ₹4,430.48 lakhs | -73.8% |
| Profit/(Loss) Before Tax | ₹2.73 lakhs | ₹47.24 lakhs | -94.2% |
| Earnings per Share (Basic) | ₹0.03 | ₹0.47 | -93.6% |
| Earnings per Share (Diluted) | ₹0.03 | ₹0.47 | -93.6% |
| Total Comprehensive Income | ₹2.73 lakhs | ₹47.24 lakhs | -94.2% |
Source: Click Here
Concord Drugs Current Market Overview
Concord Drugs is currently trading at ₹37.5 per share, down by 0.53%. The company has a market cap of ₹37.5 crore. Its stock price has ranged between ₹30.1 and ₹61.5 in the past. With a very high P/E ratio of 3,753, the company’s book value per share is ₹33.8.
It does not offer any dividend yield. Concord Drugs has a return on capital employed (ROCE) of 5.05% and a return on equity (ROE) of 1.45%. The face value of the stock is ₹10.
| Metric | Value |
|---|---|
| Current Price | ₹37.5 |
| Change | -0.53% |
| Market Cap | ₹37.5 Cr. |
| High / Low | ₹61.5 / ₹30.1 |
| Stock P/E | 3,753 |
| Book Value | ₹33.8 |
| Dividend Yield | 0.00% |
| ROCE | 5.05% |
| ROE | 1.45% |
| Face Value | ₹10.0 |
Quarterly Results
Below is a summary of Concord Drugs’s quarterly results for the periods ending December 2023, March 2024, and June 2024:
| Metric | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|
| Sales | 12.78 | 15.64 | 11.69 |
| Expenses | 12.15 | 15.29 | 10.86 |
| Operating Profit | 0.63 | 0.35 | 0.83 |
| Operating Profit Margin (OPM %) | 4.93% | 2.24% | 7.10% |
| Other Income | 0.00 | 0.00 | 0.00 |
| Interest | 0.50 | 0.50 | 0.45 |
| Depreciation | 0.39 | 0.39 | 0.34 |
| Profit Before Tax | -0.26 | -0.54 | 0.04 |
| Tax % | -3.85% | -38.89% | 50.00% |
| Net Profit | -0.24 | -0.34 | 0.03 |
| Earnings Per Share (EPS in Rs) | -0.24 | -0.34 | 0.03 |
About Concord Drugs
Concord Drugs is a prominent pharmaceutical company based in India, established in 1995. The company operates a modern, WHO-GMP certified facility that specializes in producing a wide range of high-quality pharmaceutical products.
Their offerings include ready-to-fill pellets, injectables, oral solid dosages like tablets and capsules, as well as liquid orals and dry syrups. Located in Brahmanapally Village on the Nagarjuna Sagar Highway, Concord Drugs focuses on both manufacturing and developing innovative drug delivery technologies.
They started with finished pharmaceutical formulations and have expanded into contract manufacturing, aiming to provide comprehensive solutions for their clients' pharmaceutical needs.
Check our website for more Q1 results.
Concord Drugs Q1 Results - FAQs
1. What are the net sales from operations for Concord Drugs in Q1 2024-2025?
Net sales from operations for Concord Drugs in Q1 2024-2025 were ₹1,169.29 lakhs.
2. How much did Concord Drugs’ net sales decrease compared to the previous quarter?
Concord Drugs’ net sales decreased by 74% QoQ.
3. What was Concord Drugs' other income in Q1 2024-2025?
Concord Drugs’ other income in Q1 2024-2025 was ₹0.00 lakhs.
4. What is the total revenue reported by Concord Drugs for Q1 2024-2025?
The total revenue reported by Concord Drugs for Q1 2024-2025 was ₹1,169.29 lakhs.
5. How did the cost of material consumed change for Concord Drugs in Q1 2024-2025?
The cost of material consumed for Concord Drugs decreased by 74.3% QoQ.
6. What were the total expenses for Concord Drugs in Q1 2024-2025?
The total expenses for Concord Drugs in Q1 2024-2025 were ₹1,165.20 lakhs.
7. How did Concord Drugs’ profit before tax change in Q1 2024-2025?
Concord Drugs’ profit before tax decreased by 94.2% QoQ.
8. What is the earnings per share (basic) for Concord Drugs in Q1 2024-2025?
The earnings per share (basic) for Concord Drugs in Q1 2024-2025 were ₹0.03.
9. What was the operating profit for Concord Drugs in Q1 2024-2025?
The operating profit for Concord Drugs in Q1 2024-2025 was ₹2.73 lakhs.
10. What was Concord Drugs’ previous quarter’s net sales from operations?
Concord Drugs’ previous quarter’s net sales from operations were ₹4,492.45 lakhs.